Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 20, 2024 - Issue 1
Submit an article Journal homepage
1,572
Views
0
CrossRef citations to date
0
Altmetric
Coronavirus

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages

Bradley K. Ackersona Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0816-7345View further author information
ORCID Icon,
Katia J. Bruxvoorta Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA;b Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USAView further author information
,
Lei Qiana Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Lina S. Sya Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Sijia Qiua Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Julia E. Tuberta Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Gina S. Leea Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Jennifer H. Kua Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Ana Floreaa Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Yi Luoa Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Radha Bathalaa Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Julie Sterna Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Soon K. Choia Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Harpreet S. Takhara Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Michael Aragonesa Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USAView further author information
,
Morgan A. Marksc Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USAView further author information
,
Evan J. Andersonc Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USAView further author information
,
Cindy Ke Zhouc Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USAView further author information
,
Tianyu Sunc Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USAView further author information
,
Carla A. Talaricoc Infectious Disease, Epidemiology, Moderna Inc, Cambridge, MA, USA;d Epidemiology, AstraZeneca, Gaithersburg, MD, USAView further author information
&
Hung Fu Tsenga Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA;e Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6184-6534View further author information
ORCID Icon show all
Article: 2335052 | Received 16 Jan 2024, Accepted 22 Mar 2024, Published online: 04 Apr 2024

References

  • Centers for Disease Control and Prevention. COVID data tracker: trends. [accessed 2023 Oct 7]. https://covid.cdc.gov/covid-data-tracker/#datatracker-home.
  • Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, de Silva TI, Peacock SJ, Barclay WS, de Silva TI, Towers GJ, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023 Mar;21(3):162–10. doi:10.1038/s41579-022-00841-7.
  • U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes moderna, pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose. 2022. [accessed 2023 Jun 17]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use.
  • U.S. Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes changes to simplify use of bivalent mRNA COVID-19 vaccines. 2023. [accessed 2023 Jun 17]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-changes-simplify-use-bivalent-mrna-covid-19-vaccines.
  • Tenforde MW, Weber ZA, Natarajan K, Klein NP, Kharbanda AB, Stenehjem E, Embi PJ, Reese SE, Naleway AL, Grannis SJ, et al. Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19–associated Emergency Department or urgent care encounters and hospitalizations among immunocompetent adults — VISION network, Nine States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17;71(12):1637–46. doi:10.15585/mmwr.mm7153a1.
  • Miller J, Hachmann NP, Collier AR, Lasrado N, Mazurek CR, Patio RC, Powers O, Surve N, Theiler J, Korber B, et al. Substantial neutralization escape by SARS-CoV-2 omicron variants BQ.1.1 and XBB.1. N Engl J Med. 2023 Feb 16;388(7):662–4. doi:10.1056/NEJMc2214314.
  • Lin DY, Xu Y, Gu Y, Zeng D, Sunny SK, Moore Z. Durability of bivalent boosters against Omicron Subvariants. N Engl J Med. 2023 May 11;388(19):1818–20. doi:10.1056/NEJMc2302462.
  • Link-Gelles R, Ciesla AA, Fleming-Dutra KE, Smith ZR, Britton A, Wiegand RE, Miller JD, Accorsi EK, Schrag SJ, Verani JR, et al. Effectiveness of bivalent mRNA vaccines in preventing symptomatic SARS-CoV-2 infection — increasing community access to testing program, United States, September–November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 2;71(48):1526–30. doi:10.15585/mmwr.mm7148e1.
  • U.S. Food and Drug Administration. FDA takes action on updated mRNA COVID-19 vaccines to better protect against currently circulating variants. 2023. [accessed 2023 Sept 21]. https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating.
  • Centers for Disease Control and Prevention. COVID data tracker: vaccination distribution and coverage. [accessed 2023 Jun 17]. https://covid.cdc.gov/covid-data-tracker/#vaccination-states-jurisdictions.
  • Bruxvoort KJ, Sy LS, Hong V, Lewin B, Qian L, Huang X, Holmquist KJ, Han B, Xu S. Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system. Vaccine. 2023 Nov 30;41(49):7460–8. doi:10.1016/j.vaccine.2023.11.012.
  • Lu PJ, Zhou T, Santibanez TA, Jain A, Black CL, Srivastav A, Hung M-C, Kriss JL, Schorpp S, Yankey D, et al. COVID-19 bivalent booster vaccination coverage and intent to receive booster vaccination among adolescents and adults — United States, November–December 2022. MMWR Morb Mortal Wkly Rep. 2023 Feb 17;72(7):190–8. doi:10.15585/mmwr.mm7207a5.
  • Groom HC, Crane B, Naleway AL, Weintraub E, Daley MF, Wain K, Beth Kurilo M, Burganowski R, DeSilva MB, Donahue JG, et al. Monitoring vaccine safety using the vaccine safety datalink: assessing capacity to integrate data from immunization information systems. Vaccine. 2022 Jan 31;40(5):752–6. doi:10.1016/j.vaccine.2021.12.048.
  • Bruxvoort KJ, Sy LS, Qian L, Ackerson BK, Luo Y, Lee GS, Tian Y, Florea A, Aragones M, Tubert JE, et al. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. Dec 15 2021;375:e068848. doi:10.1136/bmj-2021-068848.
  • Tseng HF, Ackerson BK, Bruxvoort KJ, Sy LS, Tubert JE, Lee GS, Ku JH, Florea A, Luo Y, Qiu S, et al. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun. Jan 12 2023;14(1):189. doi:10.1038/s41467-023-35815-7.
  • Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, Bruxvoort KJ, Tubert JE, Florea A, Ku JH, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med. 2022 May;28(5):1063–71. doi:10.1038/s41591-022-01753-y.
  • Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, Wiegand RE, Accorsi EK, Verani JR, Shang N, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022-January 2023. MMWR Morb Mortal Wkly Rep. 2023 Feb 3;72(5):119–24. doi:10.15585/mmwr.mm7205e1.
  • Stowe J, Andrews N, Kirsebom F, Ramsay M, Bernal JL. Effectiveness of COVID-19 vaccines against omicron and delta hospitalisation, a test negative case-control study. Nat Commun. 2022 Sep 30;13(1):5736. doi:10.1038/s41467-022-33378-7.
  • Chemaitelly H, Ayoub HH, AlMukdad S, Coyle P, Tang P, Yassine HM, Al-Khatib HA, Smatti MK, Hasan MR, Al-Kanaani Z, et al. Duration of mRNA vaccine protection against SARS-CoV-2 omicron BA.1 and BA.2 subvariants in Qatar. Nat Commun. 2022 Jun 2;13(1):3082. doi:10.1038/s41467-022-30895-3.
  • Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell A-M, et al. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant. N Engl J Med. 2022 Apr 21;386(16):1532–46. doi:10.1056/NEJMoa2119451.
  • Kahn R, Schrag SJ, Verani JR, Lipsitch M. Identifying and alleviating bias due to differential depletion of susceptible people in postmarketing evaluations of COVID-19 vaccines. Am J Epidemiol. 2022 Mar 24;191(5):800–11. doi:10.1093/aje/kwac015.
  • Stein C, Nassereldine H, Sorensen RJD, Amlag JO, Bisignano C, Byrne S, Castro E, Coberly K, Collins JK, Dalos J. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023 Mar 11;401(10379):833–42. doi:10.1016/s0140-6736(22)02465-5.
  • Griffith GJ, Morris TT, Tudball MJ, Herbert A, Mancano G, Pike L, Sharp GC, Sterne J, Palmer TM, Davey Smith G, et al. Collider bias undermines our understanding of COVID-19 disease risk and severity. Nat Commun. 2020 Nov 12;11(1):5749. doi:10.1038/s41467-020-19478-2.
  • Bodner K, Knight J, Hamilton MA, Mishra S. Testing whether higher contact among the vaccinated can be a mechanism for observed negative vaccine effectiveness. Am J Epidemiol. 2023 Aug 4;192(8):1335–40. doi:10.1093/aje/kwad055.
  • Henk K, Rosing F, Wolff F, Frenzel SB, van Dick R, Erkens VA, Häusser JA, Mojzisch A, Boer D. An examination and extension of the Peltzman effect during the COVID-19 pandemic. Curr Res Ecol Soc Psychol. 2023;4:100091. doi:10.1016/j.cresp.2023.100091 .
  • Falahi S, Mohamadi J, Sayyadi H, Pakzad I, Rashidi A, Naserifar R, Abdi J, Kenarkoohi A. COVID-19 vaccination, Peltzman effect and possible increase in high risk behaviors: a growing concern related to risk compensation and reduced compliance to public health protective measures after vaccines rollout. Infect Disord Drug Targets. 2022;22(8):8–12. doi:10.2174/1871526522666220419133849.
  • Fukushima W, Hirota Y. Basic principles of test-negative design in evaluating influenza vaccine effectiveness. Vaccine. 2017 Aug 24;35(36):4796–800. doi:10.1016/j.vaccine.2017.07.003.
  • Tokars JI, Patel MM, Foppa IM, Reed C, Fry AM, Ferdinands JM. Waning of measured influenza vaccine effectiveness over time: the potential contribution of leaky vaccine effect. Clin Infect Dis. 2020 Dec 17;71(10):633–41. doi:10.1093/cid/ciaa340.
  • Coe AB, Elliott MH, Gatewood SBS, Goode JR, Moczygemba LR. Perceptions and predictors of intention to receive the COVID-19 vaccine. Res Social Adm Pharm. 2022 Apr;18(4):2593–9. doi:10.1016/j.sapharm.2021.04.023.
  • Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011 Mar 15;173(6):676–82. doi:10.1093/aje/kwq433 .
  • Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring frailty in medicare data: development and validation of a claims-Based frailty Index. J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):980–7. doi:10.1093/gerona/glx229.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.